Andere Sprachen Exagen Inc.

Aktien

A2PRXT

US30068X1037

XGN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 18.04.2024			% 5 Tage	% 1. Jan.
1,429 ^USD	+2,06 %		-3,78 %	-28,20 %

18.03.	Exagen Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
18.03.	Transcript : Exagen Inc., Q4 2023 Earnings Call, Mar 18, 2024

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Exagen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18.03.
Earnings Flash (XGN) EXAGEN Reports Q4 Revenue $13.8M, vs. Street Est of $11.6M	18.03.
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results	18.03.
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results	18.03.
Exagen Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024	18.03.
Exagen Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	18.03.
North American Morning Briefing : Investors -2-	18.03.
Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum	08.03.
Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum	08.03.
Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024	07.03.
Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference	30.01.
Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance	07.01.
Exagen Inc. Reaffirms Earnings Guidance for the Full Year Ended December 31, 2023	07.01.
Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance	07.01.
Exagen Files $150 Million Mixed Shelf	20.11.
Exagen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13.11.
Earnings Flash (XGN) EXAGEN Reports Q3 Revenue $13.4M, vs. Street Est of $10.3M	13.11.
Exagen Inc. Reports Strong Third Quarter 2023 Results	13.11.
Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers	09.11.
Exagen Inc. to Participate in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum	02.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Exagen Inc.

Aktien

A2PRXT

US30068X1037

XGN

Andere Sprachen

Filter